WO2002014475A3 - Quantitative assessment of erbb/her receptors in biological fluids - Google Patents

Quantitative assessment of erbb/her receptors in biological fluids Download PDF

Info

Publication number
WO2002014475A3
WO2002014475A3 PCT/US2001/025641 US0125641W WO0214475A3 WO 2002014475 A3 WO2002014475 A3 WO 2002014475A3 US 0125641 W US0125641 W US 0125641W WO 0214475 A3 WO0214475 A3 WO 0214475A3
Authority
WO
WIPO (PCT)
Prior art keywords
erbb
receptors
biological fluids
quantitative assessment
methods
Prior art date
Application number
PCT/US2001/025641
Other languages
French (fr)
Other versions
WO2002014475A2 (en
Inventor
David A Talmage
Lorna W Role
Jianxin Bao
Original Assignee
Univ Columbia
David A Talmage
Lorna W Role
Jianxin Bao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia, David A Talmage, Lorna W Role, Jianxin Bao filed Critical Univ Columbia
Priority to AU2001284974A priority Critical patent/AU2001284974A1/en
Publication of WO2002014475A2 publication Critical patent/WO2002014475A2/en
Publication of WO2002014475A3 publication Critical patent/WO2002014475A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor

Abstract

This invention provides a method for determining the amount of a protein which selectively binds to a transmembrane isoform of a neuregulin protein and induces nuclear translocation of the isoform, in a biological sample. The invention also provides methods for detecting other functional molecules, methods for treating diseases, including neurodegenerative diseases and cancer, compounds and pharmaceutical compositions, and cells used in the methods describes herein.
PCT/US2001/025641 2000-08-16 2001-08-16 QUANTITATIVE ASSESSMENT OF erbB/HER RECEPTORS IN BIOLOGICAL FLUIDS WO2002014475A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001284974A AU2001284974A1 (en) 2000-08-16 2001-08-16 Quantitative assessment of erbb/her receptors in biological fluids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64036400A 2000-08-16 2000-08-16
US09/640,364 2000-08-16

Publications (2)

Publication Number Publication Date
WO2002014475A2 WO2002014475A2 (en) 2002-02-21
WO2002014475A3 true WO2002014475A3 (en) 2002-08-01

Family

ID=24567946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025641 WO2002014475A2 (en) 2000-08-16 2001-08-16 QUANTITATIVE ASSESSMENT OF erbB/HER RECEPTORS IN BIOLOGICAL FLUIDS

Country Status (2)

Country Link
AU (1) AU2001284974A1 (en)
WO (1) WO2002014475A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1495330B1 (en) 2002-04-12 2009-01-21 O'Dowd, Brian, F. Method of identifying transmembrane protein-interacting compounds
US20070042433A1 (en) * 2003-03-26 2007-02-22 Jianxin Bao Neuregulin protein regulation of synaptic proteins
EP2175274A1 (en) * 2008-09-26 2010-04-14 Sanofi-Aventis Methods for determining sodium-proton-exchanger ligand efficiency
AR073675A1 (en) * 2008-09-26 2010-11-24 Sanofi Aventis METHODS TO DETERMINE THE EFFECTIVENESS OF SODIUM-PROTON EXCHANGERS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070322A2 (en) * 1999-05-14 2000-11-23 The Trustees Of Columbia University In The City Of New York A-FORM OF CYTOPLASMIC DOMAIN OF nARIA (CRD-NEUREGULIN) AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070322A2 (en) * 1999-05-14 2000-11-23 The Trustees Of Columbia University In The City Of New York A-FORM OF CYTOPLASMIC DOMAIN OF nARIA (CRD-NEUREGULIN) AND USES THEREOF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARARI D. ET AL.: "Neuregulin-4: a novel growth factor that acts through the ErbB-4 tyrosine kinase", ONCOGENE, vol. 18, 1999, pages 2681 - 2689, XP000979546 *
WANG J. ET AL.: "Transmembrane neuregulins interact with LIM kinase 1, a cytoplasmic protein kinase implicated in development of visuospatial cognition", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 32, 7 August 1998 (1998-08-07), pages 20525 - 20534, XP002908400 *

Also Published As

Publication number Publication date
AU2001284974A1 (en) 2002-02-25
WO2002014475A2 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
CN102633881B (en) Antibodies directed to her-3 and uses thereof
CA2853103C (en) Point-of-care immunoassay for quantitative small analyte detection
AU2002304640A1 (en) Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells
Branstetter et al. RANK and RANK ligand expression in primary human osteosarcoma
Li et al. A gold nanoparticle-based lateral flow immunosensor for ultrasensitive detection of tetrodotoxin
WO2005108989A3 (en) Assay for antibodies
BRPI0513189A (en) methods and compositions for the detection of ovarian diseases
HUP0202532A2 (en) Human monoclonal antibody against a costimulatory signal transduction molecule (ailim) and pharmaceutical use thereof
ATE348843T1 (en) DETECTION OF TSH RECEPTOR AUTOANTIBODIES USING AFFINITY PURIFIED ANTIBODIES
BR0315161A (en) Isolated antibody, isolated polynicleotide, vector, host cell, method of producing an antibody, and, composition
WO2005060520A3 (en) ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
HRP20131047T1 (en) Identification of tumor-associated antigens for diagnosis and therapy
EA201000245A1 (en) HUMAN NEUTRALIZING ANTIBODIES TO THE NERVE GROWTH FACTOR (NGF) AS A SELECTIVE NGF METABOLIC INHIBITOR
ATE222254T1 (en) USE OF A METALLOPORPHYRIN CONJUGATE FOR DETECTING BIOLOGICAL COMPOUNDS
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
Murphy et al. Odontogenic ameloblast-associated protein nature of the amyloid found in calcifying epithelial odontogenic tumors and unerupted tooth follicles
DK1692181T3 (en) Leptin antagonist and method for quantitative measurement of leptin
CN106461670B (en) Glycated proteins test
KR20100093502A (en) Method for detecting target molecules using aptamers
CA2589054A1 (en) Detection of a therapeutic antibody in an experimental animal
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
CA2366514A1 (en) Diagnostic and therapeutic use of antibodies against the urokinase receptor
NO985904D0 (en) TIE-2 receptor ligands (TIE-ligand-3, TIE-ligand-4), and use thereof
WO2006089219A3 (en) Neoepitope detection of disease using protein arrays
WO2002014475A3 (en) Quantitative assessment of erbb/her receptors in biological fluids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP